August 2012
-
Johnson & Johnson spinout PrEP Biopharm said that it is ready to initiate a real-world trial of its PrEP-001 intranasal “viral RNA surrogate” against common respiratory viruses after the successful completion of a toxicology study… Read more . . .
-
Hikma Pharmaceuticals announced that the FDA has approved 100 mcg/50 mcg and 250 mcg/50 mcg doses of the company’s fluticasone propionate / salmeterol DPI (VR315), a generic version of Advair Diskus and that the company… Read more . . .
-
By the time DDL 2020 began its live “Christmas lectures” on December 9, more than 1,450 delegates had registered for the meeting. Although the live presentations concluded on December 11, there are still benefits to… Read more . . .
-
The EU has approved AstraZeneca’s Trixeo Aerosphere (PT010) formoterol fumarate / glycopyrronium bromide / budesonide MDI for the treatment of patients with moderate to severe COPD that is not treated adequately an ICS/LABA or LABA/LAMA combination, the… Read more . . .
-
According to Opiant Pharmaceuticals, the US Biomedical Advanced Research and Development Authority (BARDA) is providing an additional $3.5 million for development of Opiant’s OPNT003 nalmefene nasal spray for the treatment of opioid overdose. BARDA had previously provided $4.6… Read more . . .
-
TFF Pharmaceuticals announced that the first subjects have been dosed in a Phase 1b clinical trial of its dry powder voriconazole, which it is developing for the treatment of invasive pulmonary aspergillosis. The trial is… Read more . . .
-
Codagenix and vaccine manufacturer Serum Institute of India (SIIPL) have initiated a Phase 1 trial of COVI-VAC single-dose intranasal, live attenuated vaccine against SARS-CoV-2 after receiving approval from the MHRA, the companies said. Like Codagenix’s… Read more . . .
-
CDMO Vectura, which specializes in inhaled drug development and manufacturing, announced that it is adding new product development capabilities for handling highly potent APIs. The new laboratory, which will be located at the company’s Chippenham,… Read more . . .
-
The EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion regarding an expanded indication for Janssen’s Spravato esketamine nasal spray on December 10, 2020. The proposed revision would add the use of Spravato… Read more . . .
-
The US Department of Defense is providing $8.5 million to fund development of a Q-Griffithsin (Q-GRFT) nasal spray at the University of Louisville, the university said. The funding will support the PREVENT-CoV project for development… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland